A venture capital firm based in Solana Beach, CA provides seed funding to very early stage companies and also invests in Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in New York City is focused on companies in the healthcare field with a preference for Medtech, Healthcare IT, and Consumer Health. The firm is currently investing out of their second fund, and hopes to make 2-3 investments out of it this coming year. The firm invests in all stages of companies, from Series A to Series G.

The firm considers themselves opportunistic within the healthcare field when looking for investments. The firm focuses on three major categories: Medtech (Devices and Diagnostics), Healthcare IT, and Consumer Health and is opportunistic within all three. The firm tends to prefer investments within the medtech space, a space they’re more experienced in. While opportunistic, the firm prefers opportunities in the hearing, vision, heart failure, neuromodulation, and diabetes due to previous experience in these sectors. Regarding Healthcare IT interests, the firm prefers opportunities targeted towards large audiences such as healthcare systems or large patient populations.

The firm wants to see a strong CEO and Board when making investments. The firm invests in both pre-revenue and post-revenue companies. The firm typically invests alongside a syndicate of investors, but is looking to lead or co-lead more investments in their second fund. When leading or co-leading the firm requires a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An asset management group based in China operates a USD fund of $50 million that invests in healthcare and technology startups. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, and healthcare IT products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that have completed a prototype and obtained FDA clearance or are ready for FDA submission. The firm is agnostic to indication areas.

The firm is looking for experienced management teams. The firm can leverage its innovation center to assist with commercialization in the China market. The firm my request distribution rights and board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large conglomerate headquartered in China has a primary business in single-use medical devices, with a wide range of product lines in consumables, orthopedic materials, and blood purification. The group also has subsidiaries in biopharmaceutical, healthcare services, finance, and real estate. The firm is actively expanding its healthcare business in China. The group is seeking product-based collaboration opportunities with early stage medical device businesses overseas, primarily through joint venture or incubation. Typical investments range from RMB 1-30 million (US$0.1 – 4.4 M), while there is no set upper limit. The firm would also consider in-licensing opportunities.

The firm is focusing on medical devices with an elevated interest in coronary stent, vascular ultrasound, endoscope, and surgical devices. The firm is also interested in medical technologies that are complimentary to its product line, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The group prefers products that have received FDA clearance/approval or at early commercial stage, while it is also open to projects that are pending an FDA decision. The group would also consider biopharmaceutical assets in kidney diseases.

The firm is seeking strong management teams with mature products that have received or are close to receiving regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global biotech company headquartered in France is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program.

The firm is focused on oncology, rare disease, and select neuroscience drug assets. The firm is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The firm has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The firm is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity fund headquartered in Shanghai, China, was initiated through a partnership between two strategic firms. The fund mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.

The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; and biotech products in Biosimilar, Vaccines, blood products, etc. The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.

The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers company with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has strong network in China and can offer assistance in distribution and registration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC investment group founded by a pharmaceutical firm has offices in China and California, and currently manages a fund of over $50 million. The firm typically invests $500K-$1M per company with the ability to make acquisitions via its parent company of up to $100M. The firm is seeking companies globally with innovative technologies to bring to the China market, and supports FDA-approved companies to gain CFDA approval.

The firm is open to all types of medical device, diagnostic, and healthcare technology. The firm is not interested in pharmaceuticals or biotech therapeutics due to the longer development timeline, and particularly seeks late-stage technologies that are near or on-the-market generating revenue. The firm is open to all classes of devices. The firm will only look at technology that is close to FDA clearance, within 5 years of return, and has at least developed and tested a prototype with preclinical data. The firm has historically been interested in women’s health indications; women and children health-related products or services; life science-related products to be used in the research field; diagnostic kits; and immunotherapy and cell therapy services.

The firm is seeking to invest or acquire private companies. Companies with products to be introduced to China is preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com